Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

InVivo Therapeutics and the New York Mets Present Spinal Cord Injury Awareness Day

InVivo Therapeutics and the New York Mets Present Spinal Cord Injury Awareness Day

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company is teaming with the New York Mets to create Major League Baseball’s first Spinal Cord Injury Awareness Day on Sunday, September 15th at Citi Field when the New York Mets take on the Miami Marlins at 1:10 p.m. ET.

InVivo has developed a treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery after a traumatic SCI. The Company has received FDA approval to begin a first-in-man clinical trial for the treatment of acute SCI which is expected to commence in early fall.

InVivo will raise SCI awareness partly through an on-field donation to the Greater New York Chapter of the National Spinal Cord Injury Association (NSCIA) (www.nycspinalcord.org). The check presentation will take place behind home plate immediately prior to the start of the game. InVivo and the NSCIA will also be recognized throughout the game and a public services announcement, along with footage of the check presentation, will be re-aired during the game.

In addition, InVivo has donated the Modell’s Clubhouse to the NSCIA for the game, which will give fans with SCI a very unique field level experience. Information about SCI provided by the NSCIA will also be available on the field level concourse by the Jackie Robinson Rotunda throughout the game.

SCI is a devastating condition, and the average lifetime cost of care for quadriplegic patients can exceed $6,200,000. InVivo would like to encourage fans to give to local SCI fundraisers such as:

“The New York Mets have gone overboard to make sure this first SCI Awareness Day at Citi Field will be amazing,” said InVivo CEO Frank Reynolds. “We have donated more than a hundred tickets for people in chairs to experience the Mets from the field, and we expect the day to not only lead to a Mets win, but to a real uplifting of the human spirit as SCI patients and families get to experience the understanding of New York Mets fans.”

Tickets for Spinal Cord Injury Awareness Day can be purchased through www.Mets.com/InVivo or by calling (718) 559-3131. Net proceeds from the day will go towards helping people rebuild their lives after SCI by providing resources, services, and peer support through the NSCIA. Fans purchasing tickets through this offer will receive a Mets baseball cap and a 2013 Limited Edition All-Star game pin.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. In 2011, the company earned the prestigious David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company (stock symbol NVIV) is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the potential up-listing of our common stock to a national securities exchange, and the impact of any such up-listing, such as increasing liquidity an unlocking inherent value in our stock. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to up-list to a national securities exchange, as well as other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2012 and subsequent filings with the SEC.

Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.